The astronauts are now not the only group at NASA with a jacket of their own.
Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback